Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Translational Research in Oncology | OTHER |
Not provided
Not provided
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Monotherapy Dose Dose Finding - Part 1 | Experimental | TORL-3-600 |
|
| Expansion as Monotherapy - Part 2 | Experimental | TORL-3-600 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TORL-3-600 | Drug | antibody drug conjugate |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and severity of adverse events and serious adverse events | Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0 | up to 2 years |
| Maximum Tolerated Dose (MTD) | Highest administered dose with < 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants | 28 Days |
| Recommended Phase 2 Dose (RP2D) | Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data | up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate (ORR) | Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1 | up to 2 years |
| Duration of Response (DOR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Caroline Labib, PharmD | TORL Biotherapeutics, LLC | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Providence Medical Foundation | Fullerton | California | 92835 | United States | ||
| UCLA - JCCC Clinical Research Unit |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Time from CR or PR to objective disease progression or death to any cause
| up to 2 years |
| Progression Free Survival (PFS) | PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause | up to 2 years |
| Time to Response (TTR) | Time from start of treatment to complete response or partial response | up to 2 years |
| 1 Year Overall Survival (1YOS) | Proportion of participants alive at 1 year from the start of treatment to death from any cause | 1 year |
| 2 Year Overall Survival (2YOS) | Proportion of participants alive at 2 years from the start of treatment to death from any cause | 2 years |
| Number of anti-drug antibody (ADA) Positive Participants | Immunogenicity will be measured by the number of participants that are ADA positive. | up to 2 years |
| Maximum Serum Concentration of TORL-3-600 (Cmax) | PK assessment | 21 days |
| Minimum Serum Concentration of TORL-3-600 (Cmin) | PK assessment | 21 days |
| Maximum Serum Concentration of TORL-3-600 at Steady State (Cmax,ss) | PK assessment | 63 days |
| Minimum Serum Concentration of TORL-3-600 at Steady State (Cmin,ss) | PK assessment | 63 days |
| Time of Maximum Serum Concentration of TORL-3-600 (Tmax) | PK assessment | 21 days |
| Time of Minimum Serum Concentration of TORL-3-600 (Tmin) | PK Assessment | 21 days |
| Time of Minimum Serum Concentration of TORL-3-600 at Steady State (Tmin,ss) | PK Assessment | 63 days |
| Terminal Half-life (t1/2) of Serum TORL-3-600-ADC | PK Assessment | 63 days |
| Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-3-600 | PK Assessment | 21 days |
| Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-3-600 | PK Assessment | 63 days |
| Apparent volume of distribution during the terminal phase (Vz) of TORL-3-600 | PK Assessment | 63 days |
| Clearance (CL) of TORL-3-600 | PK Assessment | 63 days |
| Accumulation ratio (Rac) of TORL-3-600 | PK Assessment | 63 days |
| Los Angeles |
| California |
| 90095 |
| United States |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | United States |
| Fort Wayne Medical Oncology and Hematology Inc. | Fort Wayne | Indiana | 46845 | United States |
| Washington University School of Medicine-Siteman Cancer Center | St Louis | Missouri | 63110 | United States |
| Sarah Cannon Research Institute-Tennessee | Nashville | Tennessee | 37203 | United States |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | United States |
| University Health Network, Princess Margaret Cancer Centre | Toronto | Ontario | M5G 2M9 | Canada |
| McGill University Health Centre | Montreal | Quebec | H4A 3J1 | Canada |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |